{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:20:03Z","timestamp":1793035203655,"version":"4.5.0"},"reference-count":15,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.1507\/endocrj.ej19-0617","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T18:05:11Z","timestamp":1588269911000},"page":"841-852","source":"Crossref","is-referenced-by-count":41,"title":["A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease"],"prefix":"10.1507","volume":"67","author":[{"given":"Tomoaki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Hospital\/Chiba University Graduate School of Medicine, Chiba 260-8670, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitoshi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Hospital, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ujihara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Hospital Organization Yokohama Medical Center, Yokohama 245-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Midorikawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamami","family":"Takeda","sequence":"additional","affiliation":[{"name":"Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akina","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Global Drug Development Division, Novartis Pharma K.K., Tokyo 105-6333, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimatsu","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555\/Advanced Medical Care Center, Kusatsu General Hospital, Kusatsu 525-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Dekkers OM, Horvath-Puho E, Jorgensen JO, Cannegieter SC, Ehrenstein V, et al. (2013) Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study. J Clin Endocrinol Metab 98: 2277\u20132284.","DOI":"10.1210\/jc.2012-3582"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, et al. (2016) Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol 4: 611\u2013629.","DOI":"10.1016\/S2213-8587(16)00086-3"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Takayanagi R, Miura K, Nakagawa H, Nawata H (2000) Epidemiologic study of adrenal gland disorders in Japan. Biomed Pharmacother 54 Suppl 1: 164s\u2013168s.","DOI":"10.1016\/S0753-3322(00)80036-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Porterfield JR, Thompson GB, Young WF Jr, Chow JT, Fryrear RS, et al. (2008) Surgery for Cushing\u2019s syndrome: an historical review and recent ten-year experience. World J Surg 32: 659\u2013677.","DOI":"10.1007\/s00268-007-9387-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Valassi E, Franz H, Brue T, Feelders RA, Netea-Maier R, et al. (2017) Diagnostic tests for Cushing\u2019s syndrome differ from published guidelines: data from ERCUSYN. Eur J Endocrinol 176: 613\u2013624.","DOI":"10.1530\/EJE-16-0967"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM (2018) Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis. Pituitary 21: 631\u2013641.","DOI":"10.1007\/s11102-018-0897-z"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, et al. (2015) Treatment of Cushing\u2019s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100: 2807\u20132831.","DOI":"10.1210\/jc.2015-1818"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, et al. (2015) Effectiveness of metyrapone in treating Cushing\u2019s syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab 100: 4146\u20134154.","DOI":"10.1210\/jc.2015-2616"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Igaz P, Tombol Z, Szabo PM, Liko I, Racz K (2008) Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Curr Med Chem 15: 2734\u20132747.","DOI":"10.2174\/092986708786242921"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, et al. (2016) Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing\u2019s disease. Pituitary 19: 138\u2013148.","DOI":"10.1007\/s11102-015-0692-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Creemers SG, Feelders RA, de Jong FH, Franssen GJH, de Rijke YB, et al. (2019) Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an <i>in vitro<\/i> study. J Clin Endocrinol Metab 104: 3437\u20133449.","DOI":"10.1210\/jc.2019-00217"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Menard J, Rigel DF, Watson C, Jeng AY, Fu F, et al. (2014) Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects. J Transl Med 12: 340.","DOI":"10.1186\/s12967-014-0340-9"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13   Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, et al. (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a Phase III multicentre study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. in press. DOI: https:\/\/doi.org\/10.1016\/S2213-8587(20)30240-0","DOI":"10.1016\/S2213-8587(20)30240-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, et al. (2008) Evaluation of health-related quality of life in patients with Cushing\u2019s syndrome with a new questionnaire. Eur J Endocrinol 158: 623\u2013630.","DOI":"10.1530\/EJE-07-0762"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Beck AT, Steer RA, Brown GK (1996) Manual for the Beck Depression Inventory-II. Psychological Corporation. San Antonio, TX, USA. https:\/\/www.nctsn.org\/measures\/beck-depression-inventory-second-edition","DOI":"10.1037\/t00742-000"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/8\/67_EJ19-0617\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T23:32:10Z","timestamp":1598657530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/67\/8\/67_EJ19-0617\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej19-0617","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}